Concepts (174)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spinal Fusion | 7 | 2022 | 41 | 1.330 |
Why?
|
| Spinal Cord Diseases | 5 | 2023 | 12 | 1.100 |
Why?
|
| Spinal Cord Injuries | 3 | 2023 | 38 | 1.090 |
Why?
|
| Nerve Transfer | 3 | 2022 | 17 | 1.050 |
Why?
|
| Cubital Tunnel Syndrome | 2 | 2023 | 10 | 0.840 |
Why?
|
| Brachial Plexus | 2 | 2019 | 26 | 0.820 |
Why?
|
| Quadriplegia | 3 | 2023 | 11 | 0.790 |
Why?
|
| Equipment and Supplies | 1 | 2020 | 16 | 0.760 |
Why?
|
| Accessory Nerve | 1 | 2019 | 1 | 0.690 |
Why?
|
| Sural Nerve | 1 | 2019 | 28 | 0.660 |
Why?
|
| Spondylosis | 3 | 2023 | 3 | 0.660 |
Why?
|
| Spondylolisthesis | 3 | 2021 | 7 | 0.580 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 4 | 2014 | 6 | 0.440 |
Why?
|
| Cervical Vertebrae | 6 | 2023 | 44 | 0.430 |
Why?
|
| Ulnar Nerve | 3 | 2023 | 23 | 0.420 |
Why?
|
| Humans | 32 | 2023 | 32292 | 0.400 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2010 | 43 | 0.390 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2010 | 94 | 0.380 |
Why?
|
| Phosphatidylinositol Phosphates | 1 | 2010 | 1 | 0.370 |
Why?
|
| Membrane Proteins | 2 | 2010 | 260 | 0.350 |
Why?
|
| Proteome | 3 | 2014 | 39 | 0.310 |
Why?
|
| Proteomics | 4 | 2014 | 94 | 0.260 |
Why?
|
| Neurosurgical Procedures | 2 | 2023 | 100 | 0.260 |
Why?
|
| Shoulder | 2 | 2023 | 42 | 0.260 |
Why?
|
| Saliva | 3 | 2012 | 36 | 0.230 |
Why?
|
| Prospective Studies | 6 | 2023 | 2273 | 0.220 |
Why?
|
| Arm | 1 | 2023 | 36 | 0.220 |
Why?
|
| Neural Conduction | 1 | 2023 | 91 | 0.220 |
Why?
|
| Neck Injuries | 1 | 2022 | 14 | 0.220 |
Why?
|
| Spinal Osteophytosis | 1 | 2022 | 1 | 0.220 |
Why?
|
| Signal Transduction | 4 | 2014 | 701 | 0.210 |
Why?
|
| Upper Extremity | 4 | 2023 | 58 | 0.210 |
Why?
|
| Recovery of Function | 2 | 2023 | 201 | 0.200 |
Why?
|
| rho-Associated Kinases | 2 | 2013 | 7 | 0.200 |
Why?
|
| Reimbursement, Incentive | 1 | 2021 | 11 | 0.200 |
Why?
|
| Spinal Stenosis | 1 | 2021 | 10 | 0.200 |
Why?
|
| Decompression, Surgical | 2 | 2023 | 54 | 0.200 |
Why?
|
| Treatment Outcome | 4 | 2023 | 3358 | 0.200 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2020 | 7 | 0.190 |
Why?
|
| Spine | 1 | 2020 | 40 | 0.190 |
Why?
|
| Lumbar Vertebrae | 4 | 2021 | 98 | 0.180 |
Why?
|
| Joint Instability | 1 | 2021 | 76 | 0.180 |
Why?
|
| Cervical Plexus | 1 | 2019 | 5 | 0.170 |
Why?
|
| Male | 11 | 2023 | 19487 | 0.170 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 316 | 0.160 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 187 | 0.160 |
Why?
|
| Lumbosacral Region | 3 | 2022 | 12 | 0.150 |
Why?
|
| Hospitals | 3 | 2022 | 99 | 0.140 |
Why?
|
| Retrospective Studies | 5 | 2023 | 3513 | 0.140 |
Why?
|
| Adult | 5 | 2023 | 9467 | 0.140 |
Why?
|
| rhoA GTP-Binding Protein | 2 | 2013 | 5 | 0.130 |
Why?
|
| Cytoskeletal Proteins | 1 | 2014 | 15 | 0.120 |
Why?
|
| Systems Biology | 1 | 2014 | 9 | 0.120 |
Why?
|
| Incidence | 1 | 2017 | 1207 | 0.120 |
Why?
|
| Receptor, Parathyroid Hormone, Type 1 | 1 | 2013 | 3 | 0.120 |
Why?
|
| Tooth Diseases | 1 | 2013 | 6 | 0.120 |
Why?
|
| Adolescent | 2 | 2019 | 3571 | 0.110 |
Why?
|
| Stomatitis, Denture | 1 | 2012 | 2 | 0.110 |
Why?
|
| Osteoarthritis | 1 | 2013 | 78 | 0.110 |
Why?
|
| Salivary Proteins and Peptides | 1 | 2012 | 3 | 0.110 |
Why?
|
| Dentures | 1 | 2012 | 5 | 0.110 |
Why?
|
| Diffusion Tensor Imaging | 2 | 2022 | 32 | 0.110 |
Why?
|
| Vascular Diseases | 1 | 2013 | 66 | 0.100 |
Why?
|
| Mouth, Edentulous | 1 | 2012 | 4 | 0.100 |
Why?
|
| Middle Aged | 7 | 2023 | 11949 | 0.100 |
Why?
|
| Female | 9 | 2023 | 20125 | 0.100 |
Why?
|
| Mutation | 1 | 2013 | 503 | 0.100 |
Why?
|
| Mass Spectrometry | 1 | 2011 | 105 | 0.090 |
Why?
|
| Oncostatin M | 1 | 2010 | 2 | 0.090 |
Why?
|
| Chromatography, Gel | 1 | 2010 | 9 | 0.090 |
Why?
|
| COS Cells | 1 | 2010 | 28 | 0.090 |
Why?
|
| Circular Dichroism | 1 | 2010 | 30 | 0.090 |
Why?
|
| Protein Structure, Secondary | 1 | 2010 | 47 | 0.090 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2010 | 71 | 0.090 |
Why?
|
| Phenotype | 3 | 2023 | 656 | 0.090 |
Why?
|
| Protein Binding | 1 | 2010 | 206 | 0.090 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 287 | 0.090 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 359 | 0.090 |
Why?
|
| MAP Kinase Kinase Kinase 4 | 1 | 2009 | 1 | 0.090 |
Why?
|
| Fibroblast Growth Factor 4 | 1 | 2009 | 1 | 0.090 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2009 | 14 | 0.080 |
Why?
|
| Trophoblasts | 1 | 2009 | 10 | 0.080 |
Why?
|
| Embryo, Mammalian | 1 | 2009 | 32 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 779 | 0.080 |
Why?
|
| Muscle, Skeletal | 2 | 2023 | 514 | 0.080 |
Why?
|
| Cell Line | 3 | 2014 | 462 | 0.080 |
Why?
|
| Animals | 4 | 2014 | 7694 | 0.070 |
Why?
|
| Aged | 5 | 2023 | 10398 | 0.070 |
Why?
|
| Stem Cells | 1 | 2009 | 310 | 0.070 |
Why?
|
| Postoperative Complications | 2 | 2021 | 788 | 0.070 |
Why?
|
| Chromatography, Liquid | 2 | 2014 | 43 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 1428 | 0.060 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2014 | 60 | 0.050 |
Why?
|
| Cluster Analysis | 2 | 2014 | 131 | 0.050 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2022 | 55 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2023 | 294 | 0.050 |
Why?
|
| Fingers | 1 | 2022 | 64 | 0.050 |
Why?
|
| Hand | 1 | 2022 | 67 | 0.050 |
Why?
|
| Decompression | 1 | 2021 | 1 | 0.050 |
Why?
|
| Spinal Canal | 1 | 2021 | 1 | 0.050 |
Why?
|
| Health Expenditures | 1 | 2022 | 66 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2021 | 45 | 0.050 |
Why?
|
| Sacroiliac Joint | 1 | 2021 | 13 | 0.050 |
Why?
|
| Endothelial Cells | 2 | 2014 | 187 | 0.050 |
Why?
|
| Pain | 1 | 2023 | 305 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 161 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2022 | 786 | 0.050 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 30 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2022 | 926 | 0.040 |
Why?
|
| Prognosis | 1 | 2022 | 1523 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2023 | 1345 | 0.030 |
Why?
|
| Mice | 2 | 2014 | 2524 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2014 | 68 | 0.030 |
Why?
|
| Cytoskeleton | 1 | 2014 | 19 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 77 | 0.030 |
Why?
|
| Codon, Terminator | 1 | 2013 | 2 | 0.030 |
Why?
|
| Tooth Eruption | 1 | 2013 | 2 | 0.030 |
Why?
|
| Penetrance | 1 | 2013 | 4 | 0.030 |
Why?
|
| Frameshift Mutation | 1 | 2013 | 6 | 0.030 |
Why?
|
| Codon | 1 | 2013 | 9 | 0.030 |
Why?
|
| Thymine | 1 | 2013 | 6 | 0.030 |
Why?
|
| INDEL Mutation | 1 | 2013 | 11 | 0.030 |
Why?
|
| Introns | 1 | 2013 | 39 | 0.030 |
Why?
|
| Cytosine | 1 | 2013 | 10 | 0.030 |
Why?
|
| Adenine | 1 | 2013 | 15 | 0.030 |
Why?
|
| Exons | 1 | 2013 | 52 | 0.030 |
Why?
|
| Pedigree | 1 | 2013 | 141 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2013 | 136 | 0.030 |
Why?
|
| United States | 1 | 2022 | 3983 | 0.030 |
Why?
|
| Protein Array Analysis | 1 | 2012 | 18 | 0.030 |
Why?
|
| Candidiasis, Oral | 1 | 2012 | 10 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 2012 | 15 | 0.030 |
Why?
|
| Candida albicans | 1 | 2012 | 12 | 0.030 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2012 | 27 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2014 | 326 | 0.030 |
Why?
|
| Carbonic Anhydrases | 1 | 2012 | 4 | 0.030 |
Why?
|
| Serum Amyloid A Protein | 1 | 2012 | 5 | 0.030 |
Why?
|
| Genotype | 1 | 2013 | 742 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 502 | 0.020 |
Why?
|
| Dental Caries | 1 | 2011 | 22 | 0.020 |
Why?
|
| Specimen Handling | 1 | 2011 | 35 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 305 | 0.020 |
Why?
|
| Sjogren's Syndrome | 1 | 2011 | 35 | 0.020 |
Why?
|
| Myosin Light Chains | 1 | 2010 | 1 | 0.020 |
Why?
|
| Cardiac Myosins | 1 | 2010 | 1 | 0.020 |
Why?
|
| Amides | 1 | 2010 | 20 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2010 | 35 | 0.020 |
Why?
|
| Biosensing Techniques | 1 | 2010 | 25 | 0.020 |
Why?
|
| RNA Interference | 1 | 2010 | 77 | 0.020 |
Why?
|
| Pyridines | 1 | 2010 | 81 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2010 | 85 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 1092 | 0.020 |
Why?
|
| Cathepsins | 1 | 2009 | 1 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2009 | 14 | 0.020 |
Why?
|
| Activins | 1 | 2009 | 3 | 0.020 |
Why?
|
| Neuropeptides | 1 | 2009 | 19 | 0.020 |
Why?
|
| Cadherins | 1 | 2009 | 26 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2009 | 37 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2010 | 141 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2009 | 135 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2009 | 65 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2011 | 911 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2009 | 149 | 0.020 |
Why?
|
| Placenta | 1 | 2009 | 74 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2009 | 181 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2009 | 449 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2009 | 245 | 0.020 |
Why?
|
| Child | 1 | 2013 | 2472 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2009 | 846 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2009 | 468 | 0.020 |
Why?
|
| Young Adult | 1 | 2013 | 2626 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2009 | 773 | 0.020 |
Why?
|
| Pregnancy | 1 | 2009 | 1010 | 0.020 |
Why?
|
| Neoplasms | 1 | 2011 | 695 | 0.010 |
Why?
|